Cargando…
Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes among Malaysian patients and correlate these...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307561/ https://www.ncbi.nlm.nih.gov/pubmed/34300032 http://dx.doi.org/10.3390/ijerph18147582 |
_version_ | 1783728077439762432 |
---|---|
author | Zulkeflee, Razan Hayati Zulkafli, Zefarina Johan, Muhammad Farid Husin, Azlan Islam, Md Asiful Hassan, Rosline |
author_facet | Zulkeflee, Razan Hayati Zulkafli, Zefarina Johan, Muhammad Farid Husin, Azlan Islam, Md Asiful Hassan, Rosline |
author_sort | Zulkeflee, Razan Hayati |
collection | PubMed |
description | Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes among Malaysian patients and correlate these mutations with clinical and hematologic parameters in MPN. Mutations of JAK2V617F, CALR, and MPL were analyzed in 159 Malaysian patients using allele-specific polymerase chain reaction, including 76 polycythemia vera (PV), 41 essential thrombocythemia (ET), and 42 primary myelofibrosis (PMF) mutations, and the demographics of the patients were retrieved. The result showed that 73.6% JAK2V617F, 5.66% CALR, and 27.7% were triple-negative mutations. No MPL W515L/K mutation was detected. In ET and PMF, the predominance type was the CALR Type 1 mutation. In JAK2V617F mutant patients, serum LDH was significantly higher in PMF compared to PV and ET. PV has a higher risk of evolving to post PV myelofibrosis compared to ET. A thrombotic event at initial diagnosis of 40.9% was high compared to global incidence. Only one PMF patient had a CALR mutation that transformed to acute myeloid leukemia. JAK2V617F and CALR mutations play an important role in diagnostics. Hence, every patient suspected of having a myeloproliferative neoplasm should be screened for these mutations. |
format | Online Article Text |
id | pubmed-8307561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83075612021-07-25 Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) Zulkeflee, Razan Hayati Zulkafli, Zefarina Johan, Muhammad Farid Husin, Azlan Islam, Md Asiful Hassan, Rosline Int J Environ Res Public Health Article Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloproliferative neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes among Malaysian patients and correlate these mutations with clinical and hematologic parameters in MPN. Mutations of JAK2V617F, CALR, and MPL were analyzed in 159 Malaysian patients using allele-specific polymerase chain reaction, including 76 polycythemia vera (PV), 41 essential thrombocythemia (ET), and 42 primary myelofibrosis (PMF) mutations, and the demographics of the patients were retrieved. The result showed that 73.6% JAK2V617F, 5.66% CALR, and 27.7% were triple-negative mutations. No MPL W515L/K mutation was detected. In ET and PMF, the predominance type was the CALR Type 1 mutation. In JAK2V617F mutant patients, serum LDH was significantly higher in PMF compared to PV and ET. PV has a higher risk of evolving to post PV myelofibrosis compared to ET. A thrombotic event at initial diagnosis of 40.9% was high compared to global incidence. Only one PMF patient had a CALR mutation that transformed to acute myeloid leukemia. JAK2V617F and CALR mutations play an important role in diagnostics. Hence, every patient suspected of having a myeloproliferative neoplasm should be screened for these mutations. MDPI 2021-07-16 /pmc/articles/PMC8307561/ /pubmed/34300032 http://dx.doi.org/10.3390/ijerph18147582 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zulkeflee, Razan Hayati Zulkafli, Zefarina Johan, Muhammad Farid Husin, Azlan Islam, Md Asiful Hassan, Rosline Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title | Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title_full | Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title_fullStr | Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title_full_unstemmed | Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title_short | Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN) |
title_sort | clinical and laboratory features of jak2 v617f, calr, and mpl mutations in malaysian patients with classical myeloproliferative neoplasm (mpn) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307561/ https://www.ncbi.nlm.nih.gov/pubmed/34300032 http://dx.doi.org/10.3390/ijerph18147582 |
work_keys_str_mv | AT zulkefleerazanhayati clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn AT zulkaflizefarina clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn AT johanmuhammadfarid clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn AT husinazlan clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn AT islammdasiful clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn AT hassanrosline clinicalandlaboratoryfeaturesofjak2v617fcalrandmplmutationsinmalaysianpatientswithclassicalmyeloproliferativeneoplasmmpn |